Sébastien Mas – CEO, Skyepharma
Skyepharma stands at a defining moment. With new shareholders, expanding high-potency and bioproduction capabilities and a sharpened focus on complex oral forms, the French CDMO is positioning itself for a…
Address: 3, rue Joseph Monier, Rueil-Malmaison 92500 ,France
Tel: + 33 (0)1 58 83 60 00
With 30 000 employees and 50 subsidiaries, Bristol-Myers Squibb was up to the 11th largest pharmaceutical companies worldwide.
Aware of the expectations from healthcare professionals, patients and governments, BMS is mobilized around a clear strategy: to focus its research on therapeutic priority areas and improve the success rate at each stage of a process development, which spans over ten years.
Internally, an innovative personnel management style contributes to employee development. Externally, Bristol-Myers Squibb undertakes concrete actions to preserve the environment.
BMS FRANCE:
* 3100 employees
* 1st Group subsidiary outside the U.S.
* 7th company of the drug in France
* C.A. 2008: 1 billion €
Cardiovascular
Virology
Oncology
Pain
Neuroscience
Self-medication (OTC)
Skyepharma stands at a defining moment. With new shareholders, expanding high-potency and bioproduction capabilities and a sharpened focus on complex oral forms, the French CDMO is positioning itself for a…
ANSM’s Director General Catherine Paugam-Burtz offers a clear view of how France’s medicines agency is adapting to a fast-shifting landscape. She discusses ANSM’s role within the European regulatory system, the…
Pascaline Gervoson, CEO of PiLeJe, a family-owned French nutraceutical company, represents the second generation of leadership following her father’s founding vision in 1992. With 27 years within the organisation and…
ISISPHARMA’s story unfolds through the Dewavrin group’s evolution from textile manufacturing into a science driven portfolio spanning dermocosmetics and micronutrition. Grégoire Dewavrin explains how the brand has grown through a…
At a time when France’s healthcare landscape is being reshaped by regulatory change, market pressure, and shifting patient expectations, Fabrice Ruggeri, Country Manager of Organon France, is steering the affiliate…
Under the leadership of Nicolas Bardonnet, Promega France has expanded its role from a broad portfolio provider to a more collaborative partner supporting key human health applications. Bardonnet has integrated…
Benta Lyon is reshaping its industrial footprint with unusual speed, combining a fast-growing CDMO platform, an expanding French made generics portfolio and new sterile capabilities that will anchor its next…
argenx has moved from an antibody engineering start-up to one of Europe’s most closely-watched biotechs, advancing a pipeline that spans multiple autoimmune diseases. In this interview, François Rauch reflects on…
With over 25 years of experience at the crossroads of science and business, Pascal Villemagne, CEO of SEQENS, shares his vision for steering the French CDMO into a new era…
France’s territorial landscape is undergoing a profound shift, and departments are emerging as decisive actors in the response to medical deserts, demographic ageing and the widening gaps in prevention and…
Jerome Estampes, CFO and interim CEO of Guerbet France, discusses his journey from joining the company in 2019 through to his current dual role, navigating the challenges of generic competition,…
Alexion France is entering a pivotal phase as the rare-disease landscape becomes more competitive, more data driven and increasingly shaped by early access and clinical-trial performance. In this interview, Celine…
See our Cookie Privacy Policy Here
